Biographical Sketch
Allan Siperstein, MD, is Head of the Section of Endocrine Surgery at Cleveland Clinic. He also serves as Vice Chairman of the Division of Surgery, and Program Director for the General Surgery Residency Program and Endocrine Surgery Fellowship.
Dr. Siperstein completed his medical school training at the University of Texas, Southwestern Medical School at Dallas, and his general surgery residency and endocrine surgery training at the University of California, San Francisco. From 1990 until 1999 he was a Faculty member in the Department of General Surgery at the University of California, San Francisco. Since then he has been a Staff member at Cleveland Clinic. In addition to endocrine surgery, he has had a long interest in minimally invasive surgery and surgical sonography. Since 1992, he has been teaching coursework in intraoperative and laparoscopic ultrasound techniques.
Current research interests include thyroid and parathyroid disease, in particular molecular markers for the identification of thyroid cancers. Clinical studies have focused on minimal incision approaches to thyroid and parathyroid surgery. He has had a long interest in the development of technologies for laparoscopic thermal ablation of hepatic tumors. Current studies continue to focus on technical advances in this area, as well as the impact of the procedure on long-term survival. He is a member of many surgical organizations, including the American Surgical Association, the American Association of Endocrine Surgeons and SAGES.
Specialty Interests
adrenal disease, Advanced Laparoscopic Surgery, endocrine surgery - thyroid and parathyroid diseases and surgery, endocrine surgery (thyroid and parathyroid), laparoscopic radiofrequency ablation of liver tumors, Laparoscopic Adrenalectomy, Laparoscopic Thermal Ablation Of Liver Tumors, pancreatic endocrine tumors., Thyroid Cancer
Innovations & Patents
Radiofrequency thermal ablation
Industry Relationships
Cleveland Clinic physicians and scientists report if they
have any collaborations with the pharmaceutical or medical
device industries as part of the Cleveland Clinic’s
procedures. The Cleveland Clinic publicly discloses
payments to its physicians and scientists for speaking and
consulting of $5,000 or more per year, and any equity,
royalties, and fiduciary relationships in companies with
which they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its doctors’
connections with industry and those of their immediate
family members. As of 10/6/2008,
Dr. Siperstein has reported no financial relationship with
industry that is applicable to this listing. Patients
should feel free to contact their doctor about
relationships with industry and how the relationships are
overseen by the Cleveland Clinic. To learn more about
the Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to our
Integrity in Innovation page.
